Mycophenolate mofetil for remission induction in severe lupus nephritis

Nephron - Clinical Practice

Volumn 100, Issue 3, 2005, Pages

  Cross, Jane ^a   Dwomoa, Adu ^b   Andrews, Peter ^c   Burns, Aine ^d   Gordon, Caroline ^b   Main, John ^e   Mathieson, Peter ^f   O'Donoghue, Donal ^g   Jayne, David ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^c ST HELIER HOSPITAL   (United Kingdom)

^d ROYAL FREE HOSPITAL   (United Kingdom)

^e JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

^f SOUTHMEAD HOSPITAL   (United Kingdom)

^g HOPE HOSPITAL   (United Kingdom)

Author keywords

British Isles Lupus Assessment Group (BILAG); Complete renal remission (BILAG C); Lupus nephritis, follow up; Lupus nephritis, treatment; Mycophenolate mofetil; Partial renal remission (BILAG B); Prospective cohort study; Systemic lupus erythematosus

Indexed keywords

ANTIBIOTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CARDIOLIPIN ANTIBODY; COMPLEMENT; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DNA ANTIBODY; DOUBLE STRANDED DNA; HISTAMINE H2 RECEPTOR ANTAGONIST; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PROTON PUMP INHIBITOR; VITAMIN D;

ADULT; ARTICLE; CAUSE OF DEATH; CLINICAL ARTICLE; CLINICAL TRIAL; COMPLEMENT BLOOD LEVEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HERPES ZOSTER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LEGIONNAIRE DISEASE; LUNG EMBOLISM; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; MULTICENTER STUDY; NEPHROTIC SYNDROME; OPEN STUDY; OSTEOPOROSIS; PRIORITY JOURNAL; RATING SCALE; RELAPSE; REMISSION; RESPIRATORY TRACT INFECTION; RETINA VEIN; TAENIASIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; UTERUS CANCER; VALIDATION PROCESS; VEIN THROMBOSIS; WORLD HEALTH ORGANIZATION;

ADULT; CYCLOPHOSPHAMIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PILOT PROJECTS; PREDNISOLONE;

EID: 20944448920     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000085054     Document Type: Article

References (19)

1. Bansal VK, Beto JA: Treatment of lupus nephritis: A meta-analysis of clinical trials. Am J Kidney Dis 1997;29:193-199.
2. Halloran P, Matthew T, Tomlanovich S, Groth C, Hooftman L, Barker C: Mycophenolate mofetil in renal allograft recipients: A pooled efficacy analysis of three randomised, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Transplant Study Groups. Transplantation 1997;63:39-47.
3. Jayne D: Non-transplant uses of mycophenolate mofetil. Curr Opin Nephrol Hypertens 1999;8:563-567.
4. Romero F, Rodriguez-Iturbe B, Parra G, Gonzalez L, Herrera-Acosta J, Tapia E: Mycophenolate mofetil prevents the progressive renal failure induced by 5/6 renal ablation in rats. Kidney Int 1999;55:945-955.
5. Adu D, Cross J, Jayne D: Treatment of systemic lupus erythematosus with mycophenolate mofetil. Lupus 2001;10:203-208.
6. Hochberg M: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
7. Howie A, Ferraira M, Adu D: Prognostic value of simple measurement of chronic damage in renal biopsy specimens. Nephrol Dial Transplant 2001;16:1163-1169.
8. Isenberg D, Gordon C: From BILAG to BLIPS disease activity assessment in lupus: Past, present and future. Lupus 2000;9:651-654.
9. Chan M, Li F, Tang C: Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 2000;343:1156-1162.
10. Li L, Wang H, Lin S: Mycophenolate mofetil treatment for diffuse proliferative lupus nephritis: A multicenter clinical trial in China. Zhongua Nei Ke Za Zhi 2002;41:476-479.
11. Hu W, Liu Z, Chen H, Tang Z, Wang Q, Shen K, Li L: Mycophenolate mofetil vs. cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis. Chin Med J (Engl) 2002;115:705-709.
12. Kingdon EJ, McLean AG, Psimenou E, Davenport A, Powis SH, Sweny P, Burns A: The safety and efficacy of MMF in lupus nephritis: A pilot study. Lupus 2001;10:606-611.
13. Karim MY, Alba P, Cuadrado MJ, Abbs IC, D'Craz DP, Khamashta MA, Hughes GR: Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology (Oxford) 2002;41:876-882.
14. Ioannidis P, Boki K, Katsorida M: Remission, relapse and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int 2000;57:258-264.
15. Fraenkel L, MacKenzie T, Joseph L, Kashgarian M, Hayslett JP, Esdaile JM: Response to treatment as a predictor of long-term outcome in patients with lupus nephritis. J Rheumatol 1994;21:2052-2057.
16. Ciruelo E, Cruz J, Lopez I, Gomez-Reino J: Cumulative rates of relapse of lupus nephritis after successful treatment with cyclophosphamide. Arthritis Rheum 1996;39:2028-2034.
17. Moroni G, Quaglini S, Maccario M, Banfi G, Ponticelli C: Nephritic flares are predictors of bad long-term outcome in lupus nephritis. Kidney Int 1996;50:2047-2053.
18. Chan M, Wong W, Lau C: Prolonged follow-up of patients with diffuse proliferative lupus nephritis treated with prednisolone and mycophenolate mofetil. J Am Soc Nephrol 2001;12:1010.
19. Shaw, LM, Holt, DW, Oellerich M, Meiser B, Van Gelder T: Current issues in therapeutic drug monitoring of mycophenolic acid: Report of a roundtable discussion. Ther Drug Monit 2001;23:305-315.